EN | 日本語
English  |  日本語
Archive
U.S. FDA Grants GrayMatters Health 510(k) Clearance to Market Prism for PTSD

GrayMatters Health(GMH), one of the portfolio companies of our partner JoyVenturesand an Israeli developer of digital self-neuromodulation therapies for mental disorders, announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its flagship product, Prism for PTSD, the first non-invasive, self-neuromodulation adjunct digital therapy for post-traumatic stress disorder (PTSD).


GMH is the first to use advanced statistical models fusing EEG and fMRI data to develop biomarkers of brain-mechanism-specific activity associated with mental disorders, named EEG-fMRI-Pattern (EFP). The company’s products use these biomarkers with an interactive audio/visual interface to help patients regain control (agency) over the relevant brain activity.


“Prism for PTSD has the potential to improve the lives of the millions of Americans living with PTSD,” said Oded Kraft, Co-founder and CEO of GrayMatters Health. “Gaining FDA clearance affirms the value of bringing this innovative and clinically proven, non-invasive technology to mental disorder treatment. We are eager to place Prism in the hands of mental healthcare professionals, in the US and abroad to help patients across the world living with PTSD.”


Learn more by visiting https://www.prnewswire.com/news-releases/us-fda-grants-graymatters-health-510k-clearance-to-market-prism-for-ptsd-301777405.html